The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Introduction to Antifungal Drugs
Abstract
In the United States, only 10 antifungal drugs are currently approved by the Food and Drug Administration (FDA) for the therapy of systemic fungal infections. As shown in table 1, these drugs belong to 3 principal classes: polyenes, pyrimidines, and azoles. Drugs that belong to other classes are also approved as topical antifungal drugs, but will not be considered further here. Although conventional amphotericin B (Fungizone) remains the standard therapy for many invasive or life-threatening mycoses, this polyene drug is associated with significant toxicity, including infusion-related events, such as chills, fever, headache, nausea and vomiting, and dose-limiting nephrotoxicity [1]. In addition, the clinical efficacy of amphotericin B in some settings (e.g., mold disease such as invasive aspergillosis in severely immunocompromised patients) is suboptimal. Consequently, 3 new lipid formulations of amphotericin B (amphotericin B lipid complex, amphotericin B cholesteryl sulfate, and liposomal amphotericin B) have been developed and recently approved by the FDA. These lipid formulations offer several advantages over conventional amphotericin B, including increased daily dose of the parent drug (up to 10-fold), high tissue concentrations in the primary reticuloendothelial organs (lungs, liver, and spleen), decrease in infusion-associated side effects (especially liposomal amphotericin B), and marked decrease in nephrotoxicity [2‐3]. Although the therapeutic : toxic ratio of these compounds is clearly improved, superiority in clinical efficacy has not been definitively established in headto-head comparative trials, either a lipid formulation versus conventional amphotericin B or 1 lipid formulation versus another lipid formulation [4‐11]. Moreover, these lipid formulations of amphotericin B are considerably more expensive than conventional amphotericin B, ranging from 10- to 20-fold higher in cost per dose [3]. In addition, the optimum daily or total dose of these lipid compounds has not been established. Accordingly, unanswered questions and controversy abound about several issues relating to these 3 lipid agents [11]. For example, is 1 drug superior by pharmacologic and efficacy pa
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationAmphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Self-citationGrant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 395
Grant, S. M., & Clissold, S. P. (1989) · Drugs · doi:10.2165/00003495-198937030-00003 · Cited by 361
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Leenders, A. C. A. P., Reiss, P., Portegies, P., Clezy, K., Hop, W. C. J., Hoy, J., Borleffs, J. C. C., Allworth, T., Kauffmann, R. H., Jones, P., et al. (1997) · AIDS · doi:10.1097/00002030-199712000-00010 · Cited by 289
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219
Wanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2520 · Cited by 202
Sharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrath, S. G., Pollard, R. B., Kolokathis, A., Mildvan, D., Fan-Havard, P., Eng, R. H. K., Patterson, T. F., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.315 · Cited by 197
Goa, K. L., & Barradell, L. B. (1995) · Drugs · doi:10.2165/00003495-199550040-00007 · Cited by 194
Prevention of Amphotericin B—Induced Renal Impairment: A Review on the Use of Sodium Supplementation
Branch, R. A. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380110049010 · Cited by 194
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166
Clinical Infectious Diseases: A Practical Approach
(1998) · doi:10.1093/oso/9780195081039.001.0001 · Cited by 156
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B
Goodwin, S., Cleary, J. D., Walawander, C. A., Taylor, J. W., & Grasela, T. H. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.4.755 · Cited by 121
Anaissie, E. J., Mattiuzzi, G. N., Miller, C. B., Noskin, G. A., Gurwith, M., Mamelok, R. D., & Pietrelli, L. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.606 · Cited by 62
Use of Azoles for Systemic Antifungal Therapy
Kauffman, C. A., & Carver, P. L. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60071-x · Cited by 50
Lipid Formulations for Amphotericin B: Does the Emperor Need New Clothes?
Graybill, J. R. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-10-199605150-00011 · Cited by 45
Cited by
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Self-citationAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Clinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Metadata
- Authors
- Dismukes, W. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 653-657
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2139598390
- Cited by
- 262
- References
- 26
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.